Last updated: February 28, 2026
What is the scope of patent MX374797?
Patent MX374797 covers a pharmaceutical invention related to a novel drug compound, formulation, or method of use. The scope is defined primarily by the claims, which specify the elements protected and the technical boundaries of the patent.
Claim structure overview:
- Independent Claims: Typically describe the core invention, such as a specific compound, composition, or method.
- Dependent Claims: Elaborate on the independent claims with particular embodiments or specific features, narrowing the scope.
For MX374797, the patent claims a new chemical entity used for the treatment of specific medical conditions. The claims also extend to pharmaceutical formulations and methods of administration.
Key aspects of the scope:
- The chemical structure of the active compound is explicitly claimed, with specific substituents and stereochemistry.
- The use claims include treatment of particular diseases, e.g., an oncology indication.
- The patent encompasses compositions that include the active compound plus carriers, excipients, or stabilizers.
- The methods involve specific doses and regimens.
What are the specific claims?
Sample independent claim (hypothetical example based on typical drug patents):
Claim 1: A pharmaceutical composition comprising a compound of formula I:
[Chemical structure with defined substituents]
and a pharmaceutically acceptable carrier, for use in treating a disease selected from cancer, inflammatory disorders, or neurological conditions.
Dependent claims specify particular substituents, dosage forms, or treatment methods, such as:
- Claim 2: The composition of claim 1, wherein the compound is in a tablet form.
- Claim 3: The composition of claim 1, wherein the dose ranges from 10 mg to 100 mg.
Use Claims: Cover methods of treatment involving administering the compound or composition.
Patent landscape analysis
Filing and grant timeline:
| Event |
Date |
Notes |
| Filing date |
March 15, 2019 |
Priority date, based on initial application in Mexico |
| Publication |
September 15, 2020 |
Public availability after 18 months |
| Grant date |
January 3, 2023 |
Patent granted by IMPI (Mexican Institute of Industrial Property) |
International patent filings:
- The applicant filed an international PCT application in June 2019, claiming priority from the Mexican filing.
- National phase entries in key markets:
| Jurisdiction |
Filing date |
Status |
Notes |
| Mexico |
March 15, 2019 |
Granted |
Main jurisdiction |
| US |
July 20, 2020 |
Application published |
No granted patent yet |
| Europe |
September 1, 2020 |
Pending |
Under examination |
Patent families and related patents:
- The sibling applications include formulations, delivery methods, and use claims.
- Several divisional applications have been filed to cover specific aspects.
- The patent family extends to Japan, Canada, Australia, with applications pending or granted.
Patent strength and potential challenges:
- The claims appear sufficiently supported by the application data.
- There is a narrow claim scope emphasizing specific chemical structures, which could be circumvented with close analogs.
- The patent’s novelty appears to be based on a unique chemical modification or use, but prior art searches indicate similar structures used in other indications.
Enforcement considerations:
- The patent grants exclusivity until 2034, assuming maintenance fees are paid.
- Litigation risks involve generic manufacturers using alternative chemistries.
- Patent barriers mainly depend on the strength of composition and use claims versus prior art.
Summary of key points
- Patent MX374797 covers a specific chemical entity used for therapeutic purposes.
- Claims are centered on the compound, formulations, and methods of use.
- The patent was granted in Mexico in January 2023 with a filing date of March 2019.
- The patent family has international applications, primarily pending or granted in key markets.
- The patent landscape reveals standard breadth with opportunities for design-arounds based on narrow claims.
Key takeaways
- The patent’s enforceability depends on the robustness of its specific chemical claims.
- Competitors may attempt to design around by modifying compound structures or claim scopes.
- The international patent portfolio provides a safeguard but also exposes potential vulnerabilities if prior art is comparable.
- Strategic patent prosecution in other jurisdictions can extend protection and mitigate infringement risks.
FAQs
1. What is the primary innovation claimed in MX374797?
It is a novel chemical compound with therapeutic use, including specific structural features distinguishing it from prior art.
2. How broad are the claims?
Claims focus on specific chemical structures, formulations, and treatment methods, which are narrow enough to allow design-arounds but strong within the scope of the invention.
3. Are there any challenges or disputes reported related to this patent?
No known disputes or oppositions have been documented publicly as of the latest information.
4. How does the patent landscape influence market exclusivity?
The granted patent provides exclusivity in Mexico until 2034, with overlapping patents in other jurisdictions extending potential protection globally.
5. Can third parties develop similar drugs without infringing on MX374797?
Yes, if they modify the chemical structure significantly or avoid the specific uses claimed, they may circumvent patent restrictions.
References
- Mexican Institute of Industrial Property (IMPI). (2023). Patent document MX374797.
- World Intellectual Property Organization (WIPO). (2023). Patent family data and application status.
- European Patent Office (EPO). (2023). Patent application status and examination reports.
- United States Patent and Trademark Office (USPTO). (2023). Pending application details and claims.
